TissueTinker

TissueTinker specializes in creating 3D bioprinted tumoroids using proprietary bioactive hydrogels, offering a more accurate representation of tumor microenvironments compared to traditional 2D cultures or animal models. This approach allows for improved cell signaling and growth, crucial for understanding cancer progression and treatment. The company targets the preclinical oncology market, providing a platform that supports high-throughput analysis within a 96-well plate format. By engineering tissue-specific bioinks, TissueTinker aims to expand its library of specialized tumor models, catering to various cancer types and stages. The business model focuses on democratizing healthcare by enabling the testing of new therapeutics on diverse patient cell sources, including both patient-derived and immortalized cell lines. Revenue is generated through the development and sale of curated sample panels for nanoparticles, monoclonal antibodies, and small molecule drugs. Keywords: 3D bioprinting, tumoroids, bioactive hydrogels, preclinical testing, oncology, tumor microenvironment, high-throughput analysis, tissue-specific bioinks, cancer therapeutics, healthcare democratization.